Sam Eldessouky Biography and Net Worth

Sam Eldessouky was named Executive Vice President and Chief Financial Officer in June 2021. He joined Bausch Health in 2016 as Senior Vice President and Corporate Controller. Previously, he served as Senior Vice President, Controller and Chief Accounting Officer for Tyco International plc. During his tenure at Tyco, he played a significant role in the wholesale turnaround of Tyco's business. He also played a key role in executing the spinoffs of Covidien and Tyco Electronics in 2006 and ADT NA and Flow Control in 2012. Prior to that, Eldessouky spent ten years at PricewaterhouseCoopers (PwC), where he held several roles of increasing responsibility and served in PwC's National Office providing technical accounting guidance on complex accounting matters. Eldessouky holds a Bachelor of Science in Accountancy from Ain Shams University and a master's degree in Accounting and Finance from the University of Liverpool. He is a Certified Public Accountant and Chartered Global Management Accountant. He served as a member of the Board of Trustees of Financial Executives Research Foundation and Financial Executives International. Additionally, Eldessouky served as a member of the Global Preparers Forum, an external advisory body to the International Accounting Standards Board, from 2007 to 2013.

What is Sam Eldessouky's net worth?: The estimated net worth of Sam Eldessouky is at least $988,025.94 as of June 11th, 2021. Mr. Eldessouky owns 116,857 shares of Bausch Health Companies stock worth more than $988,026 as of April 23rd. This net worth evaluation does not reflect any other assets that Mr. Eldessouky may own. Learn More about Sam Eldessouky's net worth.
How do I contact Sam Eldessouky?: The corporate mailing address for Mr. Eldessouky and other Bausch Health Companies executives is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. Bausch Health Companies can also be reached via phone at (514) 744-6792 and via email at [email protected]. Learn More on Sam Eldessouky's contact information.
Has Sam Eldessouky been buying or selling shares of Bausch Health Companies?: Sam Eldessouky has not been actively trading shares of Bausch Health Companies during the past quarter. Most recently, Sam Eldessouky sold 17,000 shares of the business's stock in a transaction on Friday, June 11th. The shares were sold at an average price of $31.68, for a transaction totalling $538,560.00. Following the completion of the sale, the chief financial officer now directly owns 116,857 shares of the company's stock, valued at $3,702,029.76. Learn More on Sam Eldessouky's trading history.
Who are Bausch Health Companies' active insiders?: Bausch Health Companies' insider roster includes Christina Ackermann (EVP), Seana Carson (EVP), Richard DeSchutter (Director), Sam Eldessouky (CFO), Joseph Gordon (Insider), William Humphries (Insider), Steven Miller (Director), Robert Spurr (Insider), and Amy Wechsler (Director). Learn More on Bausch Health Companies' active insiders.
Are insiders buying or selling shares of Bausch Health Companies?: In the last year, insiders at the sold shares 3 times. They sold a total of 6,948 shares worth more than $57,302.63. The most recent insider tranaction occured on December, 5th when EVP Seana Carson sold 220 shares worth more than $1,623.60. Insiders at Bausch Health Companies own 8.1% of the company. Learn More about insider trades at Bausch Health Companies.
Information on this page was last updated on 12/5/2023.

Sam Eldessouky Insider Trading History at Bausch Health Companies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/11/2021	Sell	17,000	$31.68	$538,560.00	116,857

Sam Eldessouky Buying and Selling Activity at Bausch Health Companies

Bausch Health Companies Company Overview

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Today's Range

Now: $8.53

$8.43

$8.62

50 Day Range

MA: $9.29

$8.41

$10.61

2 Week Range

Now: $8.53

$5.57

$11.46

Volume

4,025,446 shs

Average Volume

2,802,447 shs

Market Capitalization

$3.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.